Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045965009> ?p ?o ?g. }
- W2045965009 endingPage "228" @default.
- W2045965009 startingPage "224" @default.
- W2045965009 abstract "Recent reports have suggested the efficacy of amrubicin (AMR) for relapsed small-cell lung cancer (SCLC). However, doses of AMR in these reports were 40 mg/m(2) or 45 mg/m(2), and severe and frequent myelosuppression were observed. Such side effects are occasionally intolerable, as serious myelosuppression may induce fatal infections. To overcome this clinical problem, we investigated whether 35 mg/m(2) of AMR administration with routine prophylactic use of granulocyte-colony stimulating factor (G-CSF) can reduce myelosuppression, while maintaining efficacy.Between July 2003 and November 2008, 30 relapsed SCLC patients receiving 35 mg/m(2)/day of AMR were evaluated. Amrubicin was administered on days 1-3 every 3 or 4 weeks. Routine prophylactic use of G-CSF was performed beginning on day 8 and continuing for at least 5 consecutive days or until neutrophils recovered to the normal level.The median number of treatment cycles was four (range 1-9). No complete responses and 13 partial responses were observed, with response rates of: overall 43% (95% confidence interval [CI]: 26-63%); sensitive cases 33% (95% CI: 10-65%); and refractory cases 50% (95% CI: 26-74%) (p=0.4651). The disease control rate (partial response and stable disease) was 80% (95% CI: 61-92%). The progression-free survival times were: overall 4.2 months (95% CI: 3.2-5.2 months); sensitive cases 4.7 months (95% CI: 2.6-5.4 months); and refractory cases 3.5 months (95% CI: 2.6-5.2 months) (p=0.7124). The median OS times were: overall 9.6 months (95% CI: 7.2-12.5 months); sensitive cases 8.4 months (95% CI: 4.6-13.4 months); and refractory cases 11.0 months (95% CI: 6.5-12.6 months) (p=0.9315). The 1-year survival rate was 33%. Regarding grade 3/4 hematological toxicities: leukopenia (47%); neutropenia (50%); anemia (30%); and thrombocytopenia (33%) were observed. Febrile neutropenia occurred in three patients (10%). Transfusions of red blood cells and platelets were performed for eight (27%) and one (3%) patients, respectively. Treatment-related deaths and grade 3/4 non-hematological toxicities were not observed at all.Considering both safety and efficacy, AMR at a dose of 35 mg/m(2) with routine prophylactic use of G-CSF may be more desirable for the treatment of relapsed SCLC in clinical practice." @default.
- W2045965009 created "2016-06-24" @default.
- W2045965009 creator A5000653374 @default.
- W2045965009 creator A5016131935 @default.
- W2045965009 creator A5021107925 @default.
- W2045965009 creator A5022022857 @default.
- W2045965009 creator A5036577393 @default.
- W2045965009 creator A5054949063 @default.
- W2045965009 creator A5058673085 @default.
- W2045965009 creator A5062454590 @default.
- W2045965009 creator A5066413780 @default.
- W2045965009 creator A5068666337 @default.
- W2045965009 creator A5072514763 @default.
- W2045965009 creator A5080938148 @default.
- W2045965009 date "2011-05-01" @default.
- W2045965009 modified "2023-09-28" @default.
- W2045965009 title "Amrubicin at a lower-dose with routine prophylactic use of granulocyte-colony stimulating factor for relapsed small-cell lung cancer" @default.
- W2045965009 cites W1919288105 @default.
- W2045965009 cites W1932169383 @default.
- W2045965009 cites W1952431753 @default.
- W2045965009 cites W1981137973 @default.
- W2045965009 cites W1985290232 @default.
- W2045965009 cites W2000159952 @default.
- W2045965009 cites W2011167367 @default.
- W2045965009 cites W2033759405 @default.
- W2045965009 cites W2034542762 @default.
- W2045965009 cites W2047853944 @default.
- W2045965009 cites W2089993835 @default.
- W2045965009 cites W2103702213 @default.
- W2045965009 cites W2103786242 @default.
- W2045965009 cites W2115465348 @default.
- W2045965009 cites W2142055223 @default.
- W2045965009 cites W2142195688 @default.
- W2045965009 cites W2147635576 @default.
- W2045965009 cites W2156373556 @default.
- W2045965009 cites W2158127925 @default.
- W2045965009 cites W2167746331 @default.
- W2045965009 cites W2180665179 @default.
- W2045965009 cites W2261287793 @default.
- W2045965009 cites W2913381773 @default.
- W2045965009 cites W4247996612 @default.
- W2045965009 doi "https://doi.org/10.1016/j.lungcan.2010.08.009" @default.
- W2045965009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20828862" @default.
- W2045965009 hasPublicationYear "2011" @default.
- W2045965009 type Work @default.
- W2045965009 sameAs 2045965009 @default.
- W2045965009 citedByCount "5" @default.
- W2045965009 countsByYear W20459650092013 @default.
- W2045965009 countsByYear W20459650092014 @default.
- W2045965009 countsByYear W20459650092019 @default.
- W2045965009 countsByYear W20459650092020 @default.
- W2045965009 crossrefType "journal-article" @default.
- W2045965009 hasAuthorship W2045965009A5000653374 @default.
- W2045965009 hasAuthorship W2045965009A5016131935 @default.
- W2045965009 hasAuthorship W2045965009A5021107925 @default.
- W2045965009 hasAuthorship W2045965009A5022022857 @default.
- W2045965009 hasAuthorship W2045965009A5036577393 @default.
- W2045965009 hasAuthorship W2045965009A5054949063 @default.
- W2045965009 hasAuthorship W2045965009A5058673085 @default.
- W2045965009 hasAuthorship W2045965009A5062454590 @default.
- W2045965009 hasAuthorship W2045965009A5066413780 @default.
- W2045965009 hasAuthorship W2045965009A5068666337 @default.
- W2045965009 hasAuthorship W2045965009A5072514763 @default.
- W2045965009 hasAuthorship W2045965009A5080938148 @default.
- W2045965009 hasConcept C121332964 @default.
- W2045965009 hasConcept C126322002 @default.
- W2045965009 hasConcept C141071460 @default.
- W2045965009 hasConcept C142424586 @default.
- W2045965009 hasConcept C2776256026 @default.
- W2045965009 hasConcept C2776694085 @default.
- W2045965009 hasConcept C2777767877 @default.
- W2045965009 hasConcept C44249647 @default.
- W2045965009 hasConcept C71924100 @default.
- W2045965009 hasConcept C87355193 @default.
- W2045965009 hasConcept C90924648 @default.
- W2045965009 hasConceptScore W2045965009C121332964 @default.
- W2045965009 hasConceptScore W2045965009C126322002 @default.
- W2045965009 hasConceptScore W2045965009C141071460 @default.
- W2045965009 hasConceptScore W2045965009C142424586 @default.
- W2045965009 hasConceptScore W2045965009C2776256026 @default.
- W2045965009 hasConceptScore W2045965009C2776694085 @default.
- W2045965009 hasConceptScore W2045965009C2777767877 @default.
- W2045965009 hasConceptScore W2045965009C44249647 @default.
- W2045965009 hasConceptScore W2045965009C71924100 @default.
- W2045965009 hasConceptScore W2045965009C87355193 @default.
- W2045965009 hasConceptScore W2045965009C90924648 @default.
- W2045965009 hasIssue "2" @default.
- W2045965009 hasLocation W20459650091 @default.
- W2045965009 hasLocation W20459650092 @default.
- W2045965009 hasOpenAccess W2045965009 @default.
- W2045965009 hasPrimaryLocation W20459650091 @default.
- W2045965009 hasRelatedWork W2003938723 @default.
- W2045965009 hasRelatedWork W2047967234 @default.
- W2045965009 hasRelatedWork W2118496982 @default.
- W2045965009 hasRelatedWork W2351796763 @default.
- W2045965009 hasRelatedWork W2364998975 @default.
- W2045965009 hasRelatedWork W2369162477 @default.
- W2045965009 hasRelatedWork W2439875401 @default.